Welcome To The Ondine Biopharma HUB On AGORACOM

Edit this title from the Fast Facts Section

Free
Message: Ondine Announces Acquisition of Exclusive License for Gold-Nanoparticle Photosen

Ondine Announces Acquisition of Exclusive License for Gold-Nanoparticle Photosen

posted on Jul 29, 2008 05:08AM

Ondine Announces Acquisition of Exclusive License for Gold-Nanoparticle Photosensitizer
Tuesday July 29, 7:00 am ET


VANCOUVER, July 29 /CNW/ - Ondine Biopharma Corporation (TSX: OBP; AIM: OBP), a medical technology company developing photodisinfection-based products, today announced that it has acquired an exclusive license for the human therapeutic use of a gold-nanoparticle photosensitizer from UCL Business PLC, the technology transfer company of University College London, London, UK.

"In vitro studies have shown that this advanced compound is one of the most potent photodisinfection agents ever developed," stated Dr. Nicolas Loebel, Ondine's Chief Technology Officer. "The compound has proven highly efficacious in killing Methicillin/multi-drug Resistant Staphylococcus aureus, (MRSA), a prominent hospital-acquired pathogen. We intend to further develop this new agent for integration into our Photodisinfection System for various medical applications."

Share
New Message
Please login to post a reply